Global NTRK Fusion Gene Positive Advanced Solid Tumor market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Treatment Type;

Targeted Therapy, Chemotherapy, Immunotherapy, Surgery, and Radiation Therapy

By Tumor Type;

Lung Cancer, Colorectal Cancer, Breast Cancer, Pancreatic Cancer, and Sarcoma

By Indication;

NTRK 1 Fusion Tumors, NTRK 2 Fusion Tumors, and NTRK 3 Fusion Tumors

By End-User;

Hospitals & Clinics, Cancer Centers, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn420595442 Published Date: May, 2025 Updated Date: June, 2025

NTRK Fusion Gene Positive Advanced Solid Tumor Market Overview

NTRK Fusion Gene Positive Advanced Solid Tumor Market (USD Million)

NTRK Fusion Gene Positive Advanced Solid Tumor Market was valued at USD 145.36 million in the year 2024. The size of this market is expected to increase to USD 221.40 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.2%.


Global NTRK Fusion Gene Positive Advanced Solid Tumor market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 6.2 %


Study Period2025 - 2031
Base Year2024
CAGR (%)6.2 %
Market Size (2024)USD 145.36 Million
Market Size (2031)USD 221.40 Million
Market ConcentrationMedium
Report Pages315
145.36
2024
221.40
2031

Major Players

  • Bayer AG
  • Cephalon, Inc.
  • Empire Genomics, LLC.
  • Exelixis, Inc
  • F. Hoffmann-La Roche Ltd
  • NeoGenomics Laboratories, Inc.
  • OncoDNA

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global NTRK Fusion Gene Positive Advanced Solid Tumor market

Fragmented - Highly competitive market without dominant players


The NTRK fusion gene positive advanced solid tumor market is witnessing notable expansion, primarily fueled by advancements in molecular diagnostics and the growing availability of precision-targeted therapies. While NTRK gene fusions are relatively rare, their detection across various tumor types is gaining clinical significance. The increasing emphasis on personalized oncology and the integration of advanced genetic profiling tools are supporting consistent market growth.

Rising Prevalence and Diagnostic Adoption
Despite their occurrence in less than 1% of solid tumors, NTRK gene fusions have become crucial markers due to their strong correlation with positive treatment outcomes. The use of next-generation sequencing (NGS) has surged by over 35%, facilitating earlier and more accurate identification of these rare mutations. This widespread adoption of advanced diagnostics is reshaping clinical decision-making and driving the adoption of precision therapies.

Therapeutic Breakthroughs Driving Demand
The introduction of TRK inhibitors has revolutionized the treatment landscape, demonstrating response rates surpassing 75% among patients with NTRK fusion-positive malignancies. These promising results have led to swift regulatory approvals and their incorporation into mainstream oncology protocols. Continuous drug development and expanding clinical trials are further enhancing the therapeutic pipeline and strengthening market potential.

Future Outlook
Several factors are accelerating market evolution, including increased genomic screening, substantial investment in cancer research, and proven efficacy of targeted treatments. With more than 40% of cancer care facilities now conducting routine testing for actionable mutations like NTRK fusions, the diagnostic and therapeutic framework is undergoing rapid transformation. The continued advancement of precision medicine is set to propel the NTRK fusion gene positive solid tumor market forward, making it a key focus area in oncology.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Treatment Type
    2. Market Snapshot, By Tumor Type
    3. Market Snapshot, By Indication
    4. Market Snapshot, By End-User
    5. Market Snapshot, By Region
  4. NTRK Fusion Gene Positive Advanced Solid Tumor Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Growth in Precision Oncology Solutions
        2. Breakthroughs in Targeted Cancer Therapies
        3. Surge in Global Oncology Trials
      2. Restraints
        1. Emergence of Drug Resistance Mutations
        2. Insufficient Validation of Predictive Biomarkers
        3. Unequal Access to Oncology Care
      3. Opportunities
        1. Expansion in Next-Gen Targeted Therapies
        2. Advancements in Novel Biomarker Research
        3. Shift Toward Personalized Cancer Care
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. NTRK Fusion Gene Positive Advanced Solid Tumor Market, By Treatmrent Type, 2021 - 2031 (USD Million)
      1. Targeted Therapy
      2. Chemotherapy
      3. Immunotherapy
      4. Surgery
      5. Radiation Therapy
    2. NTRK Fusion Gene Positive Advanced Solid Tumor Market, By Tumor Type, 2021 - 2031 (USD Million)
      1. Lung Cancer
      2. Colorectal Cancer
      3. Breast Cancer
      4. Pancreatic Cancer
      5. Sarcoma
    3. NTRK Fusion Gene Positive Advanced Solid Tumor Market, By Indication, 2021 - 2031 (USD Million)
      1. NTRK 1 Fusion Tumors
      2. NTRK 2 Fusion Tumors
      3. NTRK 3 Fusion Tumors
    4. NTRK Fusion Gene Positive Advanced Solid Tumor Market, By End-User 2021 - 2031 (USD Million)
      1. Hospitals & Clinics
      2. Cancer Centers
      3. Others
    5. NTRK Fusion Gene Positive Advanced Solid Tumor Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Bayer
      2. Teva Pharmaceuticals
      3. Empire Genomics
      4. SeraCare Life Sciences
      5. F. Hoffmann-La Roche
      6. NeoGenomics Laboratories
      7. GlaxoSmithKline
      8. OncoDNA
      9. Merck & Co.
      10. Daiichi Sankyo
      11. Deciphera Pharmaceuticals
  7. Analyst Views
  8. Future Outlook of the Market